{"id":91696,"date":"2026-11-19T16:52:00","date_gmt":"2026-11-19T16:52:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=91696"},"modified":"2026-11-20T02:17:04","modified_gmt":"2026-11-20T02:17:04","slug":"plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/","title":{"rendered":"Plasmid DNA Manufacturing Market to Reach USD 14.59 Billion by 2035 as Gene Therapy, Vaccine and Oncology Programs Scale Up"},"content":{"rendered":"<p><em>Market Valued at USD 3.10 Billion in 2026: North America Holds a 44% Share, Viral Vectors and Gene Therapy Lead, and Asia Pacific Is the Fastest-Growing Region<\/em><\/p>\n<p>Ottawa, Nov.  19, 2026  (GLOBE NEWSWIRE) &#8212; <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/b26d2ca5-2c1b-4b3c-8b5f-1b3842a5c3f4\/f7ab6e43f12b05a61452801e7609c1dcf905617e.png\" width=\"605.0px\" data-dpi=\"200\" data-filename=\"f7ab6e43f12b05a61452801e7609c1dcf905617e.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><i>Figure 1: Plasmid DNA manufacturing market snapshot, 2025 to 2035<\/i><br \/><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p>Towards Healthcare attributes growth to rising demand for cell and gene therapies, the development of organoids and the study of genetic material. From the 2026 base, the market adds USD 11.49 billion by 2035, a 4.7-fold increase. The step from 2025 (USD 2.61 billion) to 2026 is already about 18.8%, so the forecast does not depend on a late-period acceleration.<\/p>\n<p><b>Segment Intelligence: Dominant and Fastest-Growing Segments<\/b><\/p>\n<p><b>Table 2: Segment leaders and coverage<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Segment Group<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Leading Segment (2025)<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Other Segments Covered<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Why It Matters<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>By Product<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Viral vectors<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Plasmid DNA, non-viral, electroporation, lipid\/polymer, nanoparticles, others<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Viral vector programs consume plasmid inputs in every batch<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>By Application<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Gene therapy<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">DNA vaccines, immunotherapy, others<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Clinical trial volume sets the pace of plasmid orders<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>By Disease<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Infectious disease<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Cancer, genetic disorder<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Vaccine readiness keeps large-scale plasmid supply relevant<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>By Region<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">North America (44%)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Asia Pacific (fastest-growing), Europe, Latin America, Middle East and Africa<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Regional capacity decides lead times and supply security<\/td>\n<\/tr>\n<\/table>\n<p align=\"left\" style=\"text-align:left;\"><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"302.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/53d75882-7d59-4140-8440-ea3171a814f3\/0379b853b2f3309e4eb83a0200e9cae29486b0a7.png\" width=\"605.0px\" data-dpi=\"200\" data-filename=\"0379b853b2f3309e4eb83a0200e9cae29486b0a7.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><i>Figure 2: Segment leaders across the plasmid DNA manufacturing market<\/i><br \/><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>Product.<\/b> Viral vectors hold the largest share. They are used in cell and gene therapies and in vaccine delivery, and they are valued for efficient gene delivery and targeted transport of bioactive molecules. The report notes that viral vector production already needs 2 to 3 billion liters of bioreactor capacity a year, with more to come. Each of those batches starts with plasmid DNA, which is why <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3v8HvRZBZjpIuBMOFARtqn3b0ROmz7Bd2K5s3ukjk-CpZti2oxDltMLnsRh2Kr3vMsQuzrauTbayR7GYeDMnBDsiP1pXDofmNxEmdUPSnMLWaV_NMS2tXo8u7yv7GRh9dRqiQ-sTJ9p_Zpww5xSSm7YWaCl5g0VLJpLEEAZAYVlut48BryPNJ4V5-RvkxJVB\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>viral vector manufacturing<\/u><\/a> capacity and plasmid capacity tend to expand together.<\/p>\n<p><b>Application.<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uyiCKDtIf65KCS_QqWuuqJRuDDvkSMOKr8OV79Ybis5T_6Av0EGbjTjraQo_1f8OheXL53OtMCLJAm3_MAaaiiPh60lPwYwzP-lY1SaUVHh5L8oQfAKDpXFpxvGJlaLvdOCADesBQAyv6utTGzKtaTZJL3ZdHY0kFM9qCJV5AnUywpAKC1xxwHifOcnFbJcVa54mJSVsCRNRrCJzLuiAYA==\" rel=\"nofollow\" target=\"_blank\" title=\"Gene therapy accounts for the largest application share\">Gene therapy accounts for the largest application share<\/a>. It repairs, replaces or removes genes behind disease, and interest is strongest in cancer, rare diseases and genetic disorders. More than 5,000 gene therapy trials were listed with the U.S. National Institutes of Health as of 2023, and each trial needs clinical-grade starting material.<\/p>\n<p><b>Disease.<\/b> Infectious disease leads. Plasmid DNA vaccines carry particular value where conventional vaccines fall short, and the experience of COVID-19 has kept pandemic preparedness on procurement agendas. Cancer is the next large pool of demand, with new plasmid-based vaccines, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S5As4i0l8zoVmVd-DJH5hTY6ieI1XRWnmYz1lOk1Ic2iTS6BRkBavg0xl6quCB7s_P_bo1A-a3HH_ZWWKNM-C7p7ExR_8NYZ8iH38Q41Urz4LmgA3cV5pXNayC4GibspTAqa68QZSAK2rqT-NPGwVdX2DDs9t-qOEuJepgfI7jf-jdcl9m_6oQo8vCAhhXK-8fWmDDxjPpsyGrk9xpKZ_w==\" rel=\"nofollow\" target=\"_blank\" title=\"gene therapies and cell therapies in development\">gene therapies and cell therapies in development<\/a>.<\/p>\n<p><b>Regional and Country Analysis<\/b><\/p>\n<p><b>Table 3: Regional outlook<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Region<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Position<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Demand Signal<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Countries Covered<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>North America<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Leader, 44% share (2025)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Deep R&amp;D base, government programs and active collaborations<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">U.S., Canada<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Asia Pacific<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Fastest-growing<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Heavy public and private investment in biotechnology<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">China, Japan, India, South Korea, Thailand<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Europe<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Significant growth expected<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Institute and industry research, rare disease demand, public funding<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Germany, UK, France, Italy, Spain, Sweden, Denmark, Norway<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Latin America<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Significant CAGR expected<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Local biotech capacity, university partnerships<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Brazil, Mexico, Argentina<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Middle East and Africa<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Significant CAGR expected<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Local pharmaceutical and advanced therapy programs<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">South Africa, UAE, Saudi Arabia, Kuwait<\/td>\n<\/tr>\n<\/table>\n<p align=\"left\" style=\"text-align:left;\"><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>North America.<\/b> The region held 44% of 2025 revenue, a modeled USD 1.15 billion, with the U.S. well ahead of Canada. Policy is moving in its favor. The FDA&#8217;s January 11, 2026 announcement gave <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=023HdSn7flSo4q6OK3xlaMsRTM_BQnnhTfcJwZVZ-KAkrjCIt26rNrrHirWuIjDV7opj07vToQ2JMGmM_LDKCYH9vpHDVXplwy0rOpYyv2oMwU1hZEd7Wjx8zrNWlkUb9MFhz2kYjGpXwjqoUpJFWdkcUZ76sk2CiAFN6OIP02gUiBfA8Hr9SFfvTI8ZPGQB979jRi7hOAfTCIZAYFBK4RTEpS4PzVHdci6Prn8ZmUQ0R1SUCRczQsyQLpvA-Oa0YbNvx-3n5oH35XCQG518VQ==\" rel=\"nofollow\" target=\"_blank\" title=\"cell and gene therapy manufacturers added flexibility\">cell and gene therapy manufacturers added flexibility<\/a>, and its February 2026 draft guidance on the &#8220;plausible mechanism&#8221; framework sets out evidence expectations for individualized therapies. Supply is also being built close to customers. Bionova Scientific, an Asahi Kasei subsidiary, opened a plasmid facility in The Woodlands, Texas on August 12, 2025, and ProBio launched GMP plasmid DNA manufacturing at its Hopewell, New Jersey site in April 2025.<\/p>\n<p><b>Asia Pacific.<\/b> The region is expected to grow fastest, with China, India and Japan contributing most. China expects 400 million people aged 60 or above by 2030, which supports demand for advanced therapies. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=njhW_67-t3EyivL37t7SqqHzqUyu6j7q9umQnorXcvGjjX36TBBRz1ICjJCCfcEt_J5_6Y2I0OOO1ViNMA2-veU2b3sU75U4yxPbqgAuqlEOzDXMsy0OR7aWQ1jFq7yBC05ZnzCg-cWANWpEyad3G76kZymfmPPTUpOogJWcsNYFTJzxYdeN52_VO3JntZ8HTtr85X_wH1OU0eSeKg1Y2Ng3JyMGwzZinUGohgnQ2nSKg9ua6FisXuXTwwyENFfs\" rel=\"nofollow\" target=\"_blank\" title=\"India ranks 12th globally in biotechnology and has more than 800 core biotech companies\">India ranks 12th globally in biotechnology and has more than 800 core biotech companies<\/a>, with a large vaccine manufacturing base and the second-highest number of USFDA-approved plants. Population scale in both countries means vaccines and therapeutics will be needed in volume.<\/p>\n<p><b>Europe, Latin America and the Middle East and Africa.<\/b> Europe benefits from institute-led research and public funding, and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DBYm8Kg2OApklPz8mQyykVNFixxDwwP2P0NI1jMKU6P-D3YoEF9BxPZVCbbqfzOqHPYSh8KF3VlG-wcZfTbQFI33qbOM_mOraeT9iuo-B23v-QxTq9sEf8kswmMrpWJenH1JzHkFIleMO9GQ1F-jgdOcbIFpODSkbmTO2QiN12x9ut7msinttk773aIoAKbWK4tHudWRi2joBeUSQSp5NeaETr6bH0omgwg8V1uSVMiVZRnMXHOoDEZuczXX6Drd\" rel=\"nofollow\" target=\"_blank\" title=\"Germany pairs a strong pharmaceutical base with new capacity such as BioNTech's Marburg plant\">Germany pairs a strong pharmaceutical base with new capacity such as BioNTech&#8217;s Marburg plant<\/a>, opened in February 2023 for its own plasmid supply. Latin America, led by Brazil and Argentina, and the Middle East and Africa, led by the UAE and Saudi Arabia, are building local capacity to cut import dependence and delays. Skilled workers, regulatory readiness and reliable raw materials remain the gating items.<\/p>\n<p><b>What Is Changing in the Industry<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"302.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/d909b1e0-dec3-491d-a2e1-91a38eef5509\/fc355b3b711d206ed13468a612ab2e1055946d50.png\" width=\"605.0px\" data-dpi=\"200\" data-filename=\"fc355b3b711d206ed13468a612ab2e1055946d50.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><i>Figure 3: Latest company results shaping the plasmid DNA manufacturing market<\/i><br \/><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>1. A major plasmid CDMO changes hands<\/b><\/p>\n<p>Charles River completed the sale of its CDMO and Cell Solutions businesses to GI Partners in May 2026, creating Rose BioSolutions with sites in Rockville, Memphis, Northridge and Keele. The units generated USD 143 million of revenue in 2025. Rose Bio offers plasmid DNA, viral vector and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=023HdSn7flSo4q6OK3xlaD17qJ8AzSgSFuEdulCXcoMb08WG0J-NctxlFJ_S5uaz6MBGpzCAffTPir5wHOflp6942JVOdkmZbgd2l2QpC6P0qb-CwFlJzySdaIPq1E4x1hIaBdA38XJIt7bCzUznPd0QDzwsLyz0EbAKGqNr4IH4T5_RXsXr9iKdMmBOCMQl-1aWbLe_390E8qAL7GCCbg==\" rel=\"nofollow\" target=\"_blank\" title=\"cell therapy manufacturing as a standalone company\">cell therapy manufacturing as a standalone company<\/a>.<\/p>\n<p><b>What it indicates:<\/b> Capacity is moving from diversified testing groups to dedicated advanced-therapy specialists, so buyers should re-check supplier ownership, investment plans and contract terms.<\/p>\n<p><b>2. Regulators add flexibility<\/b><\/p>\n<p>On January 11, 2026 the FDA announced added flexibility for cell and gene therapy manufacturers, and in February it issued draft guidance on individualized genome-editing and RNA-based therapies. The agency stressed that the framework is a set of recommendations, not a new approval pathway.<\/p>\n<p><b>What it indicates:<\/b> Smaller, faster and more varied programs are becoming viable, which favors suppliers offering short-run, rapid-turnaround plasmid batches.<\/p>\n<p><b>3. Upstream DNA suppliers scale<\/b><\/p>\n<p>Twist Bioscience launched research-grade plasmid preps in December 2025. For fiscal 2026 (ended September 30) it reported revenue of USD 459.4 million, up 22%, and fourth-quarter revenue of USD 126.6 million, up 28%. It guided fiscal 2027 revenue to USD 550 million to USD 560 million.<\/p>\n<p><b>What it indicates:<\/b> Demand for custom DNA is compounding, and the research-grade tier is where many programs first meet a plasmid supplier.<\/p>\n<p><b>4. Large platforms report steady demand<\/b><\/p>\n<p>Thermo Fisher reported third-quarter 2026 revenue of USD 12.14 billion, up 9% with 6% organic growth, on October 21. Danaher, which owns Aldevron, reported sales of USD 6.6 billion the same day, with biotechnology core revenue up 5% and full-year adjusted EPS guidance raised to USD 8.57 to USD 8.62.<\/p>\n<p><b>What it indicates:<\/b> Bioprocess spending is improving after a soft period, which supports the capital needed for new plasmid and viral vector capacity.<\/p>\n<p><b>5. Speed becomes the selling point<\/b><\/p>\n<p>ProBio&#8217;s April 2025 service offers clinical-grade plasmid DNA from cell bank to batch release in as little as three months, and Bionova added a 10,000-square-foot plasmid development and production site in Texas in August 2025.<\/p>\n<p><b>What it indicates:<\/b> Delivery time, not list price, is becoming the main basis of competition for early-phase gene therapy sponsors.<\/p>\n<p align=\"left\" style=\"text-align:left;\"><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>Key Market Drivers, Challenges and Opportunities<\/b><\/p>\n<p><b>Key Market Drivers<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4.5pt;\"><b>Cell and gene therapy demand:<\/b> gene therapy is the largest application, and more than 5,000 trials were listed with the NIH as of 2023.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Vaccine demand:<\/b> about 140 million babies are born each year, and many vaccines require multiple doses.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Rising cancer burden:<\/b> the WHO estimated 20 million new cases in 2022 and expects more than 35 million by 2050, a 77% increase.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Infectious disease preparedness:<\/b> plasmid-based vaccines address cases where conventional vaccines fail.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Process improvement:<\/b> single-use systems, advanced purification and scalable production lower contamination risk and shorten timelines.<\/li>\n<\/ul>\n<p align=\"left\" style=\"text-align:left;\"><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>Major Challenges<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4.5pt;\"><b>Strict regulation:<\/b> genetically modified plasmids require controlled environments to prevent release, which adds time and cost.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Unstable yields:<\/b> subjective process control in traditional production produces inconsistent plasmid yields.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Unpredictable timelines:<\/b> sponsors continue to cite delivery uncertainty from plasmid manufacturers.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Portfolio churn:<\/b> Charles River exited CDMO work in 2026, and Galapagos and Takeda stepped back from cell therapy programs in late 2025.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Capability gaps in emerging regions:<\/b> Latin America and the Middle East and Africa still need skilled staff, quality systems and dependable raw materials.<\/li>\n<\/ul>\n<p align=\"left\" style=\"text-align:left;\"><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>Emerging Opportunities<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4.5pt;\"><b>Rapid-turnaround GMP supply:<\/b> three-month cell-bank-to-release services set a new reference point.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>AI-enabled process control:<\/b> machine learning can stabilize yields and improve plasmid design for stability.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Asia Pacific capacity:<\/b> China, India and Japan are the fastest-growing demand centers.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Local manufacturing in new regions:<\/b> Brazil, Argentina, the UAE and Saudi Arabia are investing in domestic supply.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Personalized and non-viral therapies:<\/b> individualized treatments and non-viral delivery formats widen the addressable use of plasmid DNA.<\/li>\n<\/ul>\n<p align=\"left\" style=\"text-align:left;\"><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>Company and Competitive Intelligence<\/b><\/p>\n<p>The report profiles 17 participants, led by VGXI, Bionova Scientific, Asahi Kasei, Catalent, Charles River, Thermo Fisher Scientific and Aldevron, alongside specialists such as Vigene Biosciences, PackGene, Plasmidfactory and Delphi Genetics. No concentration figure is published, and the 2026 ownership change at Charles River shows how quickly the map can shift. The table below summarizes the latest reported data for selected companies.<\/p>\n<p><b>Table 4: Selected company intelligence<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Company<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Role or Key Products<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Latest Reported Data<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Strategic Direction<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Thermo Fisher Scientific<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Automated plasmid purification (KingFisher PlasmidPro); bioprocessing<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 revenue USD 12.14 billion, up 9%; organic growth 6%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Automation and AI-enabled laboratories<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Danaher (Aldevron)<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Plasmid DNA through Aldevron; bioprocess tools through Cytiva<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 sales USD 6.6 billion; biotechnology core revenue up 5%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Connecting capabilities across businesses<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Rose BioSolutions (formerly Charles River CDMO)<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Plasmid DNA, viral vector and cell therapy CDMO<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Divested units earned USD 143 million in 2025; Charles River Q3 revenue USD 982.7 million<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Dedicated advanced-therapy manufacturing under GI Partners<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Twist Bioscience<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Synthetic DNA and research-grade plasmid preps<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">FY2026 revenue USD 459.4 million, up 22%; Q4 up 28%<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Capacity build-out; FY2027 guidance USD 550 to 560 million<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Asahi Kasei (Bionova Scientific)<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Plasmid DNA CDMO<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Opened a 10,000-square-foot Texas plasmid site on August 12, 2025<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Strengthening the U.S. advanced-therapy supply chain<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>ProBio<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">GMP plasmid DNA and viral vectors<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">GMP plasmid service launched April 2025 at Hopewell, New Jersey<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Integrated plasmid and vector manufacturing at one site<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>BioNTech<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">In-house plasmid DNA production<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Marburg plant opened February 2023<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Self-supply for infectious disease and cancer candidates<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Sartorius (Polyplus)<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">RepCap plasmid pPLUS AAV-RC2<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Launched March 2024 for AAV2 manufacture<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Raw materials for viral vector production<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Plasmidfactory<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Plasmid and minicircle DNA<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">GMP facility under construction<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Adding GMP grade to research and high-quality grades<\/td>\n<\/tr>\n<\/table>\n<p align=\"left\" style=\"text-align:left;\"><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"302.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/18940e95-7e08-48bf-ad9c-283b3905ffa0\/98b7c3d81ccdf94c0f62fe677078828fd9e626cd.png\" width=\"605.0px\" data-dpi=\"200\" data-filename=\"98b7c3d81ccdf94c0f62fe677078828fd9e626cd.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><i>Figure 4: Reported company growth against the 18.77% market CAGR<\/i><br \/><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>Customer and Buyer Intelligence<\/b><\/p>\n<p><b>Table 5: Buyer groups and purchase signals<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Target Account Group<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Decision-Makers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Purchase Signals<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Commercial Opportunity<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Gene therapy developers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Chief technical officers, heads of CMC<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">IND filings, trial starts, AAV and lentiviral scale-up<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Long-term GMP plasmid supply agreements<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Vaccine and mRNA developers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Heads of manufacturing, supply chain leaders<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">New infectious disease programs, pandemic preparedness funding<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Large-batch and multi-year capacity reservations<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Oncology and cell therapy developers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">VPs of technical operations, procurement<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Rising cancer pipelines, personalized therapy launches<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Rapid-turnaround, small-lot plasmid batches<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>CDMOs and in-house manufacturers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Site heads, sourcing managers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Facility expansions, automation upgrades<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Purification systems, raw materials, quality testing<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Academic and research centers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Principal investigators, core facility managers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Government grants, trial sponsorship<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Research-grade plasmids and custom design<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Early-stage biotech companies<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Founders, R&amp;D leaders<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Seed and Series A funding, preclinical milestones<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Bundled design, research-grade and GMP onramps<\/td>\n<\/tr>\n<\/table>\n<p align=\"left\" style=\"text-align:left;\"><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>How Towards Healthcare Supports Decision-Making<\/b><\/p>\n<p><b>Master Dataset.<\/b> Consolidates plasmid DNA manufacturing size, segment, regional and company data into one structured source, so strategy teams can test capacity, pricing and share assumptions without rebuilding the numbers each quarter.<\/p>\n<p><b>Towards Healthcare Quadrant.<\/b> Positions plasmid suppliers and CDMOs on capability and market momentum, which helps sponsors shortlist partners and helps suppliers see where they stand after moves such as the Rose BioSolutions spin-out.<\/p>\n<p><b>Interactive Intelligence Dashboard.<\/b> Lets users filter by product, application, disease and region to see where viral vector, gene therapy and infectious disease demand is concentrating, and to track Asia Pacific against North America.<\/p>\n<p><b>Quality and Manufacturing Intelligence.<\/b> Covers the operating metrics that decide plasmid sourcing, including yield, supercoiled content, turnaround time and GMP capacity, and supports technical due diligence on supplier shortlists.<\/p>\n<p><b>Customized Research.<\/b> Delivers tailored analysis, such as build-versus-buy for in-house plasmid production, regional entry planning, or a competitor deep dive, to support investment and partnering decisions.<\/p>\n<p><b>Table 6: Solutions overview<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Solution<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>What It Provides<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>How It Helps<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Master Dataset<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Structured market, segment, regional and company data<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Faster, consistent forecasting and benchmarking<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Towards Healthcare Quadrant<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Competitive positioning of suppliers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Supplier shortlisting and partnership screening<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Interactive Intelligence Dashboard<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Filterable views by product, application, disease, region<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Demand tracking and territory prioritization<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Quality and Manufacturing Intelligence<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Yield, purity, turnaround and capacity benchmarks<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Technical due diligence and sourcing decisions<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Customized Research<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Bespoke studies on a defined question<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Investment, entry and partnering decisions<\/td>\n<\/tr>\n<\/table>\n<p align=\"left\" style=\"text-align:left;\"><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>Why Continuously Updated Intelligence Matters<\/b><\/p>\n<p>Plasmid DNA markets move on short cycles. <b>Monthly<\/b> updates capture facility openings, launches and partnerships, such as ProBio&#8217;s service launch or Bionova&#8217;s Texas site. <b>Quarterly<\/b> updates follow earnings, where Thermo Fisher, Danaher, Charles River and Twist each reported within a three-week window this autumn. <b>Six-monthly<\/b> reviews track regulatory movement, including the FDA&#8217;s January and February 2026 actions and the final form of its guidance. <b>Annual<\/b> updates re-base the forecast, supplier map and buyer priorities against the 2035 outlook.<\/p>\n<p><b>Strategic Outlook<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4.5pt;\"><b>CEOs and CXOs:<\/b> a market growing at 18.77% a year will reach about 4.7 times its 2026 size by 2035, so capacity and ownership decisions made now compound for a decade.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Strategy and Business Development:<\/b> the Charles River divestiture shows that CDMO assets are being repriced, which opens acquisition, carve-out and partnership options.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>R&amp;D:<\/b> FDA flexibility and the plausible mechanism draft guidance favor small, fast programs that need research-grade and GMP plasmids on short timelines.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Procurement:<\/b> qualify more than one plasmid source and compare delivery time, since services quoting cell bank to batch release in three months are redefining expectations.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Investors:<\/b> the 44% North America share and Asia Pacific&#8217;s faster growth point to two different return profiles, scale in the U.S. and expansion in China, India and Japan.<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Manufacturers and Suppliers:<\/b> Twist&#8217;s fiscal 2027 guidance of USD 550 to 560 million and Thermo Fisher&#8217;s automation push suggest that purification, automation and quality systems are where suppliers can differentiate.<\/li>\n<\/ul>\n<p><b>Company Ecosystem<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"462.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/9e0f4d2b-6332-4bda-b5bf-1f0942ed8332\/e740635b161c5f3d97aca6c8e97c0b448ad0ce1c.png\" width=\"643.0px\" data-dpi=\"200\" data-filename=\"e740635b161c5f3d97aca6c8e97c0b448ad0ce1c.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><i>Figure 5: Plasmid DNA manufacturing company ecosystem<\/i><br \/><i>Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and Researcher<\/i><\/p>\n<p><b>Call to Action<\/b><\/p>\n<p>Decision-makers who need segment-level detail, company profiles and the full 2025 to 2035 forecast can access the complete Plasmid DNA Manufacturing Market report, request a sample or speak with the research team.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:3pt;\"><b>Report: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmZ_AVQOfPPxjUN7ZA1VWnOcyLV4QVKGhlV2dmSO_QlsUlPLvMaliKUoyChkMncoIzzX_zc0OkGzs8AtJxb2V-ZJYe_6KigtoCSLZqHPrFOTCTz9_qzphz0j-uihK--OALf79mK4V0qzTEhw8hGo5wFO82rWrYxfDIJTyf0XoA9avrCt_fI9Yg0FFavx1_ETDkMUF806_ofWsMI-wt0ueI9g==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/plasmid-dna-manufacturing-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:3pt;\"><b>Request a sample: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmGvnY6YhzW8IvQLA8o38Geu9P1Cc5hCI-UVGhtJZUDkE8fPrRtazzu44WZhUmBfGH_Y3d0-O35Jz2qHptbegMYytJxClwCkeQnxk4fb5k1N0=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/sample\/5239<\/u><\/a><\/li>\n<li style=\"margin-bottom:3pt;\"><b>Checkout: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmncdeE2yepRnBAAkYJ8QJMHjjBAJoqub_weic6HThRaBbZpUVg2eOMfASFLVLoZOAG98eGkreGp-NsEwnASB0WMnYagrwWQcf2IVpFVLpMqA=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/checkout\/5239<\/u><\/a><\/li>\n<li style=\"margin-bottom:3pt;\"><b>Schedule a meeting: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqms6nhOdTWXM0EPcDT0Dm78ddHycNusIB9e98sgRV_MshoEAYn81Jxq8yqiYx9d0YNojxHqI2CKYtad-jGHeBrxjlw93ponFDJad6QSw42iulMrJvW8QXptB1vGw4fq_Ov\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/schedule-meeting<\/u><\/a><\/li>\n<\/ul>\n<p><b>Fill out the form for relevant samples, case studies, and examples. <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VqND8W9vlw2vh7tWK3d77pl9uPF4xs8HHADKXMpLvPOwi5OYGNTMq7NaUuhf1_qH9l1TG50A3C3Dtz0I4lkKzq4YQAlGUIECwEqmANyMW8FfHtmcds5uMTfFfBPuBddh\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>sales@towardshealthcare.com<\/u><\/a><\/p>\n<p><b>Related Reports<\/b><\/p>\n<ol style=\"list-style-type:decimal;\">\n<li style=\"margin-bottom:2.5pt;\">US Plasmid DNA Contract Manufacturing Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmn5kmV6aZw0PEpxGz-q9MxFr2uZ9DT-ulVTBGDOKRsMhO1U3GcOJy3h2vLftz0lYUl9SXJj7Oa60IqsaRh1xsc_qN320SWYpAA6TeQpSuZIuBsojN-M3t4_Jgf1qI-pqfiDjVRE9aQJm7PX2cBLyEnd7N5kiDsUQmZcLswP3eRb4s8U0k9QQCMuP4syOjnuum5bDIX7yZxq8vC_cgdemAn5SiqCKZR2SJPe-l8Fhh7ns=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/us-plasmid-dna-contract-manufacturing-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Viral Vector Manufacturing Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmu_vBtKXvCKniYyQzXcXi62Pcjq2b54X-Ue-MQ3Eg82D6MnC1743jXchIAm26OlBlun_CtxGAuf3zPr70rbcOw9XrIXVjdzKPFlHy4MahWNOEdDULPj8av1iut6v7EH1H19XIHFCbli6MBXbMF0hG766y51I5EfxMw0jtv1xazo8fA3FxOKKHcD9K6Hx8funkuwzTSw9WN38m-DZMJ8TnqA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/viral-vector-manufacturing-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Viral Vector and Plasmid DNA Manufacturing Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmu_vBtKXvCKniYyQzXcXi66gSP2K7iRZdz2gDgZCBb4u-XERIi3i6LICQL4odS_o2m_ZpAlA4fAlb5Q_-eancceyspd0hLSKWwxcFNHZsVkJ-jjmSAHAOB5uHBKKVDh-AaMfP7M43faWKS0YEGKSe4EqwWFeWfOhrKHv84dG3iLZmwPBwcY-xCq51lTr0MpfrnzqDltbNlASeuMrCYbhVqQlCXV98a3ZDLpsmFllz_wBgmm7D49xH50ddStOPQ_91\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/viral-vector-and-plasmid-dna-manufacturing-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">US Viral Vector and Plasmid DNA Manufacturing Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqm14X8XjTLpfQKO-EO6dECiLeciKi-69q3RwgVkxh7ToAmWW9ovIuk9GAjisGXOQNOLinEDWAfSb5XbODJlIjarstlSLoiUnCJ8i2UFqOqw6xRqyf7ffCLieeuHa_Z-s3zGPmqR89Rg9jALdT_v0Hti827VmzDk97eKo-VvNGtjZ59t2PMlQwfFIsIrkN-Kkviph2wBzPymT7xR_LeUvyag2jj7bfLDn2U6vLbB8C3nH3ZfZ-nS_nRqglEVxLQFBOw\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/us-viral-vector-and-plasmid-dna-manufacturing-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Viral Vector Gene Therapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmu_vBtKXvCKniYyQzXcXi66sfr7Q0Qm3nu7p39abEG40BFMqbBzy-L93CJmh33rbQWqSciy6yF8TNWHWVPHU2W8uz3fJf5RZwRJHch4aG_zsiB6h1y10qSdLpcekLfmGiC0vZ1SgMBxrazF0BkTL5R9Mbqzei6DhU34CRznyRpRrIX8EJrvFksdJW9cYTxEOJR6_f1ysDGIWi2WCfhpX7hA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/viral-vector-gene-therapy-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Viral Vector Development Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmu_vBtKXvCKniYyQzXcXi6xXJYHH9uP34Ii-Gw6L0Dl_HmAX-x-KPtFFnsvV9PaEHOUXp3gpwTZDVkSgwOfhTmih8XpYfhQtORT-b3p8-uQ3kclmvyMrLUBar1ylgQYeYD4Sd5k1KexPixQmiaVW89r9FMqNRoXo1GQI8oSujqaGMwPVBEvx7lA5IPJiV4Ry_\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/viral-vector-development-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Viral Vector-Based Cell and Gene Therapy CDMO Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmu_vBtKXvCKniYyQzXcXi68-T85gXF-RMvW-XBEw2oq2wWuQanVgAtoPCstVG19G7lUOWER3y230nadbmOb_ARln9Pt6Zywqujo1l-GsYaWQMUWlySfdVZuqiq7FoGVRnaRLU92wnCUGYif4kZnlQCFYrq8_2zLBvwK3v07Qh2tPpsrpUdNdtf8bSi7NahOju5CwhxF_BLIAQsn0TuMShTkEsAzygAHZuQ4J3uGDFclEjiZrrS5ziE9uMltLnQpHk\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/viral-vector-based-cell-and-gene-therapy-cdmo-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Gene Therapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmlj5AFmpZ4JRIr5rxW_LIIxiNQGS9KyPiNiqx5Xp0UD0tcCSzO-S4miXLKNOXEjaDXJCDogLvJfhnvH6pzM6nRDr45F5YH3D7-9sAZGylIvEOQMI2_KXeiyc5AUhBC3OrOB5MhZzerVGCkq2zhkBOQT5L7hnYklRQ-TCYt3Y1yYw=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/gene-therapy-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Gene Vector Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmOtBCY5br3y_82Rb2VDZ-82xmmkgR7EyRtDLTfgmid0NRPFF_t_MkxqkO10zjI6c-6hygD5QL-neFry-AJj0pTdeVWSv1Cki14ELfT75K_KzdlO6-lUrUPI8EMpfMLgvqQgfdl_79v1QAJcZz7d5mroUUiDIS03DpV4p2Lj8P1r4=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/gene-vector-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Cell and Gene Therapy Manufacturing Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmSPpOqenVUIsnUtucip7t7ikxlSueX65d_atPafDJlD11TVl-AxF4fEvxZyaGaXypGieT9N75Uwn3GOcxaBc8-CvHYUEJK9YgU6EHgU9zXpPon45ITgzB5ppoVnfwFigaxkid56003i2-6JNmKQHnB1D_Y30-hDewYGAs68OcY9NEm6mbWZS36ceVez36x2Ad00d1jKrLzPHnPQg37U1tz-mX8FGZZDWrwLvc2m0b9uqtYVDX5shwHPS7sV-ZYf9rSInpjoyiIryxe4YzV_vZllwEy1BI2KdC2qmDB90CDlo=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/cell-and-gene-therapy-manufacturing-market-experiencing-significant-growth<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Cell and Gene Therapy Services Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmSPpOqenVUIsnUtucip7t7rsDawfLi082FXOZbmcQ6PQ31TJU3E0feyZACPqTm3d2zwD3qcV_MfbMgkGG0JK1ZGynTo1amO3lSL3BRKlAZN1o6eeBHmf6XzokD0Eh06oe__w1-nGfk6n2FadqpIuiN8snM8w_pm4nkjzmx1WJIiPOx79cGd8qcGyIXEbPihgIW4c-l1PzdNXHiCrFdxjAYg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/cell-and-gene-therapy-services-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">US Cell and Gene Therapy CDMO Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqms9iFW82CPlfn7GA_WLECHp_8tIeVgAVBd0dGwD39auoFxz4MWKIsgRxeC1QTKixHvEomyf7lF68rnOtZf-7AYfjDbyRFSyaj4_qS2U76eAnFY9B6q5L19h5OwlkUdvPm0WNmx1tdoGQql_1344wCAHccI7GaovSz-k8ucjBCZhn7RxwnNkzg6tEDwq8u6IMF0bI_0EwFclPo7mZ1m_fI1Q==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/us-cell-and-gene-therapy-cdmo-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">US Cell and Gene Therapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqms9iFW82CPlfn7GA_WLECHp_8tIeVgAVBd0dGwD39auqJvxwSciAae1TRP5bz8P8UfkMQAqZsxDLtQPmzQePVG01qU-CoH2vX_-Tmt24VwumIHgH-fIAR5Yx9PiR21WlBg9vyfbhS0Kv0L3ZIb6E7Rb4J8n5AHdBEEmfSpFx7VqOZ9AUxzIM0txdAu7uOsPus\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/us-cell-and-gene-therapy-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">North America Cell and Gene Therapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmy-_0g8LijHuBvUFm8EXNKs7BXkGUdrpd3dEaAI4OEbcv8OLlRSQinKpIIymdB-qStipUGBmdSbQJOyxjAjvaxcydqD-JXAGnPve6-EOo8Ck7JYoStahhxlBL_SpA9VGzWw8jTHNDXQU3vg8rGDVMBPEO-CBN2w5b4aPTuYkGJybcDjO90YXGFUYR4ByaHb1HilIuSmbw7N5XLIwulfTDv9GAtfTlDw1fik-CtCPv0lU=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/north-america-cell-and-gene-therapy-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Cell and Gene Therapy for Oncology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmSPpOqenVUIsnUtucip7t7rnSs6_fKz_w4fWgN1ZxbVfzebC3mmoDpoA05n_zwKWh_M3rKw1cu3XopBXD4h91g2o67E9JGmeewLXTY0ZOYQF0jfu2wBvEk6yZepCvtj4JBZrYOnJehboUpR_mBGtB1ia1ekv4Cb4-6S55hmEG3iAgGmMC3Fbch8vixuUa_hMwTfaPeiRhcI9qvcQHWymnG_zhcia1fclgzQ5ta0-sVOg=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/cell-and-gene-therapy-for-oncology-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Cell Therapy Monitoring Kits Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmz56aMUluuWZSizuVl_nhwiODw6ZsDotEUrDz1C31ZtpAew3-efy1NnGfafAiLCfFN6zLhy4NoJ76fZVFdPleIrCau-FMCfknBJwTubgiR6pL7gZBg82hq-Y6z2LLQtz5FoVdzoryrl9IASDTPUwvXKOOIgfD6N6_KiKQPMtVjeHkw01HAJeso-iixdif8N_L0dyOpzq98sALlUDWSCbyOg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/cell-therapy-monitoring-kits-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Cell and Gene Therapy Thawing Equipment Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmSPpOqenVUIsnUtucip7t7nqgWNzb3_moBCTzNd2aeXvHS6QIXo6_yE2-53Yk0IPr93ArBK_c1qls_nW0BU0eTAjTDHbWwbwyRTZ_1LJF992cNRyJP85mPNpC1nlK9fwk17k25enQotIfdTHiVvrBQ_rnSPbXKzzj3DVv5-eAcpEqsld_U5zcb5C69qRaC7va9Q5ScB451i9d_KUXHJ9G_05yM-bITSWq0ZfQaZ6019U=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/cell-and-gene-therapy-thawing-equipment-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Cell Therapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmz56aMUluuWZSizuVl_nhwi7eqrHT9MNiLNkWCz4K3_zLrYK-TbKxLZ1B-geYzz-yPqLJb13gLNrCmeTY59dpvYJ5WzuNY5DQFoVo0owu_Ma60GOVAkaOwnIqF26tjYDhDjk_KFV9PQyQy1gI7TpheiDGBs7tmPEsemt7YV15RI8=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/cell-therapy-market-sizing<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Biotechnology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmYRxZsvjnmdsGiHrPSxoY8vZoveZ8n8nHJ8GbVsHnFok49DG41aVWXi3QolDHJ1c20oyGwzEqGkxfmgDyjN8i0xctOMgXIkfWIoj8Ujz1MqomYaLaU8Cd5p2e02AYtYhbd0McddWOtu6ToE7hwchiQA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/biotechnology-market<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\">Hearing Loss Gene Therapy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXWkJWn_4RQ-FobjwpUakqmPDdXwCPAi2eD5WMqLFK3B6CXczE2DxsIJF1QrPvsQPZVv2E4TwXiNFtp71AtQwA7G7VWva5rLFlUZCSy9W6wvTTDGNcj_MfWw7Yzzr36S5dpKr7eyDbrl-3Qe-YKHzlISZ2eFelVHfKuZlM_QsB3f2pC3_MMl_Gyfs71JyVEs3rivfhcobVxFPIrd24Mhw63vtQmC79IAHB9kbrkdISzzA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/insights\/hearing-loss-gene-therapy-market-sizing<\/u><\/a><\/li>\n<\/ol>\n<p><b>About Towards Healthcare<\/b><\/p>\n<p>Towards Healthcare is a healthcare-focused research and consulting firm that delivers market intelligence, forecasts and advisory support across biotechnology, pharmaceuticals, diagnostics, medical devices and life sciences. Its analysts combine expert interviews, secondary research and a proprietary database to help leadership teams size markets, assess competitors and plan investment. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I-mWtlkjaxQM99fbSOy0gaAUSqeX7Kilto6i6MOm1xttcPO3qavIfrW-TCiCBg1Rz0MGbM2QJA8A9kEUsVXGTn6rrAZ0Rz0mfyhmWIJhtF0zgZXqxDIXtuiQhJ-2rDgV\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardshealthcare.com\/<\/u><\/a><\/p>\n<p><b>Our Partners<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:2.5pt;\"><b>Precedence Research: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTNvLT0HVVLBhPVs9jzDvkVO_S8Sg_dbsd1VduP9F4xkEy3i9bTwkWjcX_c4vjMVevM0toG5wCN5CvehkXd2Aw8PE016dpbpuMxpI3B-1M_PfgV6yRYsJ6Shqsu8di56dSQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.precedenceresearch.com\/<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\"><b>Towards Packaging: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfXUCdcJS6uv8zLSUJ1tqQRrbDspiLbWEX2ZND_RgXPtAXiISlOGSLqqgweaQT6GQ51Wa_ezhwZiLN65kw5zrEZb\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardspackaging.com\/<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\"><b>Towards Chemical &amp; Materials: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDWSjH5gZl7oEMxxIsCPwfVSPeJDARWdL_TVVS073z1-U7SkNexkPU9UJviXZgtCNSa7V_-jNSB3diNW0jicGgbVx1mXCcBYmtqKFlDYH5swEhzYIYhTBj8eHPloBjP9eQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.towardschemandmaterials.com\/<\/u><\/a><\/li>\n<\/ul>\n<p><b>Connect With Us<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4.5pt;\"><b>USA:<\/b> +1 804 441 9344<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>APAC:<\/b> +61 485 981 310 or +91 87933 22019<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Singapore:<\/b> +65 3105 1271<\/li>\n<li style=\"margin-bottom:4.5pt;\"><b>Europe:<\/b> +44 7383 092 044<\/li>\n<li style=\"margin-bottom:7pt;\"><b>Email: <\/b><a href=\"mailto:sales@towardshealthcare.com\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>sales@towardshealthcare.com<\/u><\/a><\/li>\n<\/ul>\n<p><b>Social Media<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:2.5pt;\"><b>LinkedIn: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTIfBO_bA0bXMkviCHSmzAVTj7ul-o23QJdQe1jYpozIlBFnOjbBFFTqBabQLSaCHdgAtJv7Uic48OlYlXNEv27o3G60wvFETGxFJ3wShjWKWjR8BQPMxVmgOUuTdenWZEJMu4H1jCTpnlcxB9kLV7mcZyDlbQYFCL-CJyX8E1s1HxrUdmC6n9FT1cdtQiRF3wMlj7NTYbTYC_7frVdb3dYEA1PpwXY5_LAcUtEpTRoPg\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.linkedin.com\/company\/towards-healthcare-research-and-consulting<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\"><b>X: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTEiXcsYx28ERtZjbURi3zKXjplGFWjBeYlUXOqjm2b4pZ4zz3H1sPRUjJ0LkLctX9-0cpVsZjRFwLIUEoyQdhlZ1lZnYSamJgend8s4flDrQ\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/x.com\/TowardsHealths<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\"><b>Medium: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTDtkDSZ610ph13uJKWuyAwPFrR8UAW41_a3AhGbMpp0p9CVuMIkfE5Rb04e_xcC2x6XZXIBIIT_q6rT7g5ZawVhJvmsTy95N_EAMzM7Aixb_AIqdIBu1xMW_Q7vFIA4F1Q==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/medium.com\/@TowardsHealthcare<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\"><b>Instagram: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTPNs1tnjdDn8Mq3YIP-er0GEectjwlErtfRVZsbTAFn_ib47QGchVemAYgkdw4LRz2IX5R7bwdOokty5u6raAMLX2rWrivqk4ejbtLlzA5Z7zY99xFk2oBQwUycuT4Qyk848Nh0P0WaqooDkYDBgAc0=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.instagram.com\/towards_healthcare<\/u><\/a><\/li>\n<li style=\"margin-bottom:2.5pt;\"><b>YouTube: <\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=liNFpEkRLfsSDjA00OrKTAaPCzVvrld79lyiBHSHoremmy2y8SMPNgipXPQd0ED7UVDo7w2Y4M0OMZcVGNXRIMvl-pGDbaqdFuXXxid0QbDBRltfLVVeSdTTA8MGgsNXZRxyOVSFeTKu7OS8aET9pdKMcW3PYeqkUjHUDKjHl0Q=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>https:\/\/www.youtube.com\/@TowardsHealthcare<\/u><\/a><\/li>\n<\/ul>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/OWMwNDNjYjMtNmY0Yi00MjU5LTg1ODEtMTg5NmNiNzU3NzAwLTEyMTM4NDktMjAyNi0xMS0xOS1lbg==\/tiny\/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Market Valued at USD 3.10 Billion in 2026: North America Holds a 44% Share, Viral Vectors and Gene Therapy Lead, and Asia Pacific Is the Fastest-Growing Region Ottawa, Nov. 19, 2026 (GLOBE NEWSWIRE) &#8212; Figure 1: Plasmid DNA manufacturing market snapshot, 2025 to 2035Sources: Expert Interview, Secondary Sources, Towards Healthcare Database, Towards Healthcare Analysts and [&#8230;]\n","protected":false},"author":1,"featured_media":91697,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-91696","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Plasmid DNA Manufacturing Market to Reach USD 14.59 Billion by 2035 as Gene Therapy, Vaccine and Oncology Programs Scale Up - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Plasmid DNA Manufacturing Market to Reach USD 14.59 Billion by 2035 as Gene Therapy, Vaccine and Oncology Programs Scale Up\" \/>\n<meta property=\"og:description\" content=\"Market Valued at USD 3.10 Billion in 2026: North America Holds a 44% Share, Viral Vectors and Gene Therapy Lead, and Asia Pacific Is the Fastest-Growi\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-19T16:52:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-20T02:17:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Plasmid DNA Manufacturing Market to Reach USD 14.59 Billion by 2035 as Gene Therapy, Vaccine and Oncology Programs Scale Up\",\"datePublished\":\"2026-11-19T16:52:00+00:00\",\"dateModified\":\"2026-11-20T02:17:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/\"},\"wordCount\":2849,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/\",\"name\":\"Plasmid DNA Manufacturing Market to Reach USD 14.59 Billion by 2035 as Gene Therapy, Vaccine and Oncology Programs Scale Up - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-11-19T16:52:00+00:00\",\"dateModified\":\"2026-11-20T02:17:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Plasmid DNA Manufacturing Market to Reach USD 14.59 Billion by 2035 as Gene Therapy, Vaccine and Oncology Programs Scale Up\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Plasmid DNA Manufacturing Market to Reach USD 14.59 Billion by 2035 as Gene Therapy, Vaccine and Oncology Programs Scale Up - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/","og_locale":"en_US","og_type":"article","og_title":"Plasmid DNA Manufacturing Market to Reach USD 14.59 Billion by 2035 as Gene Therapy, Vaccine and Oncology Programs Scale Up","og_description":"Market Valued at USD 3.10 Billion in 2026: North America Holds a 44% Share, Viral Vectors and Gene Therapy Lead, and Asia Pacific Is the Fastest-Growi","og_url":"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-11-19T16:52:00+00:00","article_modified_time":"2026-11-20T02:17:04+00:00","og_image":[{"width":2400,"height":1200,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Plasmid DNA Manufacturing Market to Reach USD 14.59 Billion by 2035 as Gene Therapy, Vaccine and Oncology Programs Scale Up","datePublished":"2026-11-19T16:52:00+00:00","dateModified":"2026-11-20T02:17:04+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/"},"wordCount":2849,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/","url":"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/","name":"Plasmid DNA Manufacturing Market to Reach USD 14.59 Billion by 2035 as Gene Therapy, Vaccine and Oncology Programs Scale Up - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-11-19T16:52:00+00:00","dateModified":"2026-11-20T02:17:04+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/plasmid-dna-manufacturing-market-to-reach-usd-14-59-billion-by-2035-as-gene-therapy-vaccine-and-oncology-programs-scale-up\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Plasmid DNA Manufacturing Market to Reach USD 14.59 Billion by 2035 as Gene Therapy, Vaccine and Oncology Programs Scale Up"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/91696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=91696"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/91696\/revisions"}],"predecessor-version":[{"id":91698,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/91696\/revisions\/91698"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/91697"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=91696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=91696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=91696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}